长期补充Omega-3多不饱和脂肪酸联合多领域干预对记忆抱怨老年人认知功能的影响(MAPT):随机安慰剂对照试验
MAPT试验纳入1680名70岁以上有记忆抱怨的非痴呆社区老年人,随机分为多领域干预联合Omega-3多不饱和脂肪酸(PUFA)、多领域干预联合安慰剂、单用Omega-3 PUFA或安慰剂四组,随访3年。主要结局为复合认知Z评分变化,结果显示三种干预与安慰剂相比均无显著差异,干预未引发安全担忧。
要点
- 多领域干预联合Omega-3 PUFA、单用多领域干预或单用Omega-3 PUFA均未显著延缓3年认知下降。
- 各组严重不良事件发生率相似,干预未提出新的安全性问题。
- 有效预防或延迟认知障碍的多领域干预策略及目标人群仍有待确定。
核心结论
- 在70岁以上有记忆抱怨的非痴呆老年人中,为期3年的多领域干预和Omega-3 PUFA补充,单独或联合使用,对认知下降均无显著影响。
研究设计与样本
- 多中心、随机、安慰剂对照、优效性试验,四个平行组,在法国和摩纳哥的13个记忆中心进行。
- 纳入1680名非痴呆、70岁及以上、社区居住且有自发记忆抱怨、一项工具性日常生活活动受限或步速缓慢的老年人,随机分配至四组。
- 多领域干预包括43次小组课程(整合认知训练、体力活动和营养建议)及三次预防性咨询;Omega-3 PUFA组每日服用两粒胶囊,提供800 mg二十二碳六烯酸(DHA)和225 mg二十碳五烯酸(EPA)。
- 主要结局为改良意向治疗人群中基线至36个月复合Z评分的变化,该评分组合四项认知测试。
主要发现
- 改良意向治疗人群(n=1525)中,三个干预组与安慰剂组相比,3年认知下降均无显著差异。
- 至少发生一次严重不良事件的比例:联合干预组36%(146例)、多领域干预联合安慰剂组34%(142例)、Omega-3 PUFA组33%(134例)、安慰剂组32%(133例);治疗相关死亡4例(多领域干预联合安慰剂组2例,安慰剂组2例)。
关键数值与推荐
- 干预未提出新的安全性问题,严重不良事件或其他不良事件组间无差异。
临床怎么用
- 对于有记忆抱怨的老年人群,不应常规推荐长期Omega-3 PUFA补充或多领域干预来预防认知下降,因本研究未显示显著获益。
- 需进一步研究确定有效的多领域干预策略及目标人群,尤其在真实世界环境中。
局限性
- 研究人群限于70岁以上有记忆抱怨、一项工具性日常生活活动受限或步速缓慢的社区老年人,结论外推需谨慎。
- 多领域干预组件无法对参与者和研究 staff 设盲。
- 随访时间为3年,长期效果未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No large trials have been done to investigate the efficacy of an intervention combining a specific compound and several lifestyle interventions compared with placebo for the prevention of cognitive decline. We tested the effect of omega 3 polyunsaturated fatty acid supplementation and a multidomain intervention (physical activity, cognitive training, and nutritional advice), alone or in combination, compared with placebo, on cognitive decline. METHODS: The Multidomain Alzheimer Preventive Trial was a 3-year, multicentre, randomised, placebo-controlled superiority trial with four parallel groups at 13 memory centres in France and Monaco. Participants were non-demented, aged 70 years or older, and community-dwelling, and had either relayed a spontaneous memory complaint to their physician, limitations in one instrumental activity of daily living, or slow gait speed. They were randomly assigned (1:1:1:1) to either the multidomain intervention (43 group sessions integrating cognitive training, physical activity, and nutrition, and three preventive consultations) plus omega 3 polyunsaturated fatty acids (ie, two capsules a day providing a total daily dose of 800 mg docosahexaenoic acid and 225 mg eicosapentaenoic acid), the multidomain intervention plus placebo, omega 3 polyunsaturated fatty acids alone, or placebo alone. A computer-generated randomisation procedure was used to stratify patients by centre. All participants and study staff were blinded to polyunsaturated fatty acid or placebo assignment, but were unblinded to the multidomain intervention component. Assessment of cognitive outcomes was done by independent neuropsychologists blinded to group assignment. The primary outcome was change from baseline to 36 months on a composite Z score combining four cognitive tests (free and total recall of the Free and Cued Selective Reminding test, ten Mini-Mental State Examination orientation items, Digit Symbol Substitution Test, and Category Naming Test) in the modified intention-to-treat population. The trial was registered with ClinicalTrials.gov (NCT00672685). FINDINGS: 1680 participants were enrolled and randomly allocated between May 30, 2008, and Feb 24, 2011. In the modified intention-to-treat population (n=1525), there were no significant differences in 3-year cognitive decline between any of the three intervention groups and the placebo group. Between-group differences compared with placebo were 0·093 (95% CI 0·001 to 0·184; adjusted p=0·142) for the combined intervention group, 0·079 (-0·012 to 0·170; 0·179) for the multidomain intervention plus placebo group, and 0·011 (-0·081 to 0·103; 0·812) for the omega 3 polyunsaturated fatty acids group. 146 (36%) participants in the multidomain plus polyunsaturated fatty acids group, 142 (34%) in the multidomain plus placebo group, 134 (33%) in the polyunsaturated fatty acids group, and 133 (32%) in the placebo group had at least one serious emerging adverse event. Four treatment-related deaths were recorded (two in the multidomain plus placebo group and two in the placebo group). The interventions did not raise any safety concerns and there were no differences between groups in serious or other adverse events. INTERPRETATION: The multidomain intervention and polyunsaturated fatty acids, either alone or in combination, had no significant effects on cognitive decline over 3 years in elderly people with memory complaints. An effective multidomain intervention strategy to prevent or delay cognitive impairment and the target population remain to be determined, particularly in real-world settings. FUNDING: French Ministry of Health, Pierre Fabre Research Institute, Gerontopole, Exhonit Therapeutics, Avid Radiopharmaceuticals.
引用
- Andrieu S, Guyonnet S, Coley N, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017. PMID: 28359749. doi:10.1016/S1474-4422(17)30040-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。